| 8.98 0.43 (5.03%) | 04-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 15.79  |
1-year : | 19.44 |
| Resists | First : | 13.52 |
Second : | 16.64 |
| Pivot price | 11.6 |
|||
| Supports | First : | 8.46 | Second : | 7.03 |
| MAs | MA(5) : | 8.88 |
MA(20) : | 12.66 |
| MA(100) : | 14.71 |
MA(250) : | 14.6 |
|
| MACD | MACD : | -2.1 |
Signal : | -1.7 |
| %K %D | K(14,3) : | 3.3 |
D(3) : | 2 |
| RSI | RSI(14): 20.6 |
|||
| 52-week | High : | 21.7 | Low : | 8.46 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RCEL ] has closed above bottom band by 27.0%. Bollinger Bands are 226.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 9.23 - 9.29 | 9.29 - 9.35 |
| Low: | 8.42 - 8.49 | 8.49 - 8.56 |
| Close: | 8.86 - 8.98 | 8.98 - 9.09 |
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.
Fri, 12 Apr 2024
Little Excitement Around AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues As Shares Take 39% Pounding - Simply Wall St
Fri, 12 Apr 2024
AVITA Medical Slides As Insider Purchases Lose Another US$77k - Simply Wall St
Sun, 25 Feb 2024
AVITA Medical, Inc. (NASDAQ:RCEL) Just Reported And Analysts Have Been Lifting Their Price Targets - Yahoo Finance
Fri, 23 Feb 2024
AVITA Medical, Inc. (NASDAQ:RCEL) Q4 2023 Earnings Call Transcript - Yahoo Finance
Thu, 22 Feb 2024
AVITA Medical Inc (RCEL) Reports Robust Revenue Growth in Q4 and Full-Year 2023 - GuruFocus.com
Thu, 22 Feb 2024
AVITA Medical, Inc. (RCEL) Q4 2023 Earnings Call Transcript - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 26 (M) |
| Shares Float | 25 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 28 (%) |
| Shares Short | 726 (K) |
| Shares Short P.Month | 578 (K) |
| EPS | -1.4 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.9 |
| Profit Margin | -70.6 % |
| Operating Margin | -86.5 % |
| Return on Assets (ttm) | -25.4 % |
| Return on Equity (ttm) | -52.9 % |
| Qtrly Rev. Growth | 50 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.95 |
| EBITDA (p.s.) | -1.64 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -38 (M) |
| Levered Free Cash Flow | -24 (M) |
| PE Ratio | -6.42 |
| PEG Ratio | -0.1 |
| Price to Book value | 4.7 |
| Price to Sales | 4.6 |
| Price to Cash Flow | -6.08 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|